Haemonetics Stock Climbs As Analysts Hike Price Targets

Haemonetics Corporation stocks have been trading up by 15.77 percent following upbeat sentiment around its latest business performance.

Live Update At 16:46:49 EDT: On Tuesday, August 18, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 15.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

HAE has shifted from a slow grinder to a momentum name on traders’ screens. After weeks grinding in the high-$70s to mid-$80s, Haemonetics broke out hard. From the 2026/07/24 close near $78.78, HAE pushed into the low-$90s by 2026/08/12, then exploded to a 2026/08/18 high of $106.67 before closing at $104.65.

That is a clear uptrend with higher highs and higher lows. The intraday tape on the latest session shows tight action between roughly $104 and $106, with repeated support around $104 and sellers appearing near $106.50. For short-term traders, HAE is acting like a strong, liquid breakout holding above prior resistance in the low-$90s.

Under the hood, Haemonetics is not some story stock with no earnings. Q1 revenue came in at $339.4M and net income at about $33.0M. A roughly 59% gross margin, 7% net margin, and about 11%-12% pretax margin show a solid, profitable med-tech franchise. A price-to-sales around 3.1 and P/E near 44 tell traders the market is willing to pay up for this growth. Debt is meaningful, but coverage is strong and liquidity is solid, with a current ratio above 3.

Why Traders Are Watching HAE Momentum

Traders are crowding into HAE because the story lines up on three key fronts: earnings momentum, guidance, and Wall Street validation. First, the numbers. Haemonetics dropped a fiscal Q1 adjusted EPS print of $1.14 versus $0.87 expected. That is not a small beat. Revenue of $339.4M also topped the $327.9M consensus, telling traders the upside is being driven by real demand, not just cost cuts.

Management highlighted share gains in Plasma, continued strength in Blood Management Technologies, and a return to growth in Interventional Technologies. When a med-tech name like Haemonetics fires on all cylinders across segments, traders pay attention. On top of that, the company raised full-year guidance and nudged FY27 revenue and EPS growth targets up to 5%-8% from 4%-7%. That is a measured bump, but it signals confidence that this is a durable growth runway, not a one-quarter fluke.

The Street piled on after the print. Bank of America took its Haemonetics target from $93 to $100 and reiterated a Buy after hosting the CEO, calling for best-in-class performance and a valuation re-rating by FY27. Raymond James went even further, hiking its Haemonetics target to $105 with an Outperform. Baird moved to $96, Barrington to $95, all with bullish calls, while BofA Securities and others now sit around a roughly $96.90 consensus.

Citi is the cautious voice in the room, lifting its Haemonetics target from $79 to $92 but staying Neutral. That nuance matters for traders: the story is strong, but valuation is no longer cheap. The brief premarket softness after the beat-and-raise shows some profit-taking and positioning, not a broken thesis.

Conclusion

For active traders tracking HAE, the setup is straightforward: strong fundamentals are now aligned with an aggressive, confirmed breakout on the chart. Haemonetics delivered a clean beat on both earnings and revenue, raised near-term and FY27 guidance, and showcased momentum across Plasma, Blood Management Technologies, and Interventional lines. The balance sheet still carries leverage, but analysts like Barrington explicitly point to improving profitability and room to reduce debt by fiscal 2027.

On the sentiment side, Haemonetics now has a cluster of higher targets from Bank of America, Raymond James, Baird, Barrington, and BofA Securities, with a consensus near the high-$90s and a bullish outlier at $105. Citi’s Neutral at a $92 target helps anchor the upper end of the risk/reward debate and keeps fast money from getting complacent. For short-term traders, that creates a band of expectations to trade against while HAE holds above former resistance in the low-$90s.

The key from here is discipline. If Haemonetics keeps executing toward that 5%-8% growth lane into FY27, the Street’s “valuation re-rating” narrative stays intact. If margins or growth slip, this premium multiple can compress in a hurry. As Tim Sykes likes to say, “Patterns repeat, but you still have to manage your risk — cut losses quickly, protect your account, and only ride momentum when the trend is truly on your side.” As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This trading-focused perspective underscores why risk management and position sizing remain critical even when a ticker is breaking out. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

• Penny Stocks Trading Guide
• Best Penny Stocks Under $1 to Buy Today
• Top 8 Penny Stocks to Watch on Robinhood

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

• AI Penny Stocks
• Robinhood Penny Stocks
• Top Biotech Stocks